Athenex Inc.

The firm serves as debtor counsel in the chapter 11 bankruptcy of Athenex, Inc., a clinical-stage biopharmaceutical company and developer of cancer therapies. The debtor voluntarily filed for bankruptcy in May 2023 to divest its assets while seeking to maximize value for shareholders.

Our website uses cookies to enhance site navigation, analyze site usage, and assist in our marketing efforts. By continuing to browse this website, you agree to our Privacy Policy.